Quzyttir Injection
NDC Package 70720-100-25

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Quzyttir (cetirizine hydrochloride) injection is qUZYTTIR™ is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. This formulation utilizes a injection delivery system. Marketed by Tersera Therapeutics Llc, this product is identified by NDC 70720-100 and is authorized under FDA application NDA211415.

Identification & Billing

NDC Package Code
70720-100-25
Package Description
25 VIAL, GLASS in 1 CARTON / 1 mL in 1 VIAL, GLASS (70720-100-01)
Product Code
70720-100
11-Digit Billing Format
70720010025
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Quzyttir
Non-Proprietary Name
Cetirizine Hydrochloride
Substance Name
Cetirizine Hydrochloride
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
CETIRIZINE HYDROCHLORIDE 10 mg/mL
Pharmacologic Class
Usage Information
QUZYTTIR™ is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Regulatory & Marketing

Labeler Name
Tersera Therapeutics Llc
Product Type
Human Prescription Drug
FDA Application #
NDA211415
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-13-2019
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70720-100). Click a package code to view its specific billing and regulatory data.

70720-100-10
1 VIAL, GLASS in 1 CARTON / 1 mL in 1 VIAL, GLASS (70720-100-01)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70720-100-25 identifies a specific commercial package of 25 vial, glass in 1 carton / 1 ml in 1 vial, glass (70720-100-01) of Quzyttir, a human prescription drug labeled by Tersera Therapeutics Llc. This injection is formulated for intravenous use and contains cetirizine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Tersera Therapeutics Llc on November 13, 2019. The current certification is valid through December 31, 2027.

How is this Tersera Therapeutics Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70720010025. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70720-100-25
11-Digit CMS (5-4-2)
70720-0100-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.